Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The purpose of the study is to investigate the clinical effects of multiple (28 day) twice-daily doses of OC000459 in comparison to placebo on clinic lung function (FEV1) in mild to moderate asthmatics with an FEV1 of 60-80% of predicted and requiring only short acting inhaled B2-adrenergic agonists for symptomatic control.
Epistemonikos ID: 5a3226306251e0af8831ab80398199147d8fb98a
First added on: Jul 12, 2022